On Wednesday, Shares of Corrections Corp Of America (NYSE:CXW), lost -0.76% to $32.55.
Corrections Corp of America declared its financial results for the second quarter of 2015.
Second Quarter 2015 Highlights
- Revenue of $459.3 million raised 11.8% from the preceding year quarter
- Diluted EPS up 14.6% to $0.55 from $0.48
- Adjusted Diluted EPS up 12.2% to $0.55 from $0.49
- FFO per diluted share up 8.8% to $0.74 from $0.68
- AFFO per diluted share up 7.4% to $0.73 from $0.68
Net income generated in the second quarter of 2015 totaled $65.3 million, or $0.55 per diluted share, contrast to $55.7 million, or $0.48 per diluted share, generated in the second quarter of 2014. Not taking into account an asset impairment in connection with the sale of a non-core asset in the preceding year, net income totaled $58.0 million, or $0.49 per diluted share, during the second quarter of 2014. Funds From Operations (FFO) was $87.5 million, or $0.74 per diluted share, during the second quarter of 2015, contrast with $79.4 million, or $0.68 per diluted share, during the second quarter of 2014. Adjusted Funds From Operations (AFFO) was $86.0 million, or $0.73 per diluted share, during the second quarter of 2015, contrast with $79.6 million, or $0.68 per diluted share, during the second quarter of 2014.
Corrections Corporation of America, together with its auxiliaries, owns and operates privatized correctional and detention facilities in the United States. It owns, operates, and manages prisons and other correctional facilities; and provides inmate residential and prisoner transportation services for governmental agencies.
Shares of TherapeuticsMD Inc (NYSEMKT:TXMD), declined -0.90% to $6.61, during its last trading session.
TherapeuticsMD, declared its second quarter financial results for the period ended June 30, 2015.
Second Quarter and Recent Developments
- Net revenue for the company’s prescription prenatal vitamin business raised to about $4.8 million for the second quarter of 2015 contrast with about $3.8 million for the second quarter of 2014.
- Net loss was about $27.2 million for the second quarter of 2015, contrast with about $10.9 million for the second quarter of 2014, reflecting costs associated with the company’s continued enrollment of patients in two phase 3 clinical trials for its novel hormone therapy product candidates.
- Accomplished patient enrollment in the Rejoice Trial, a phase 3 clinical trial of TX-004HR (estradiol in VagiCap), an applicator-free vaginal estradiol product candidate for the treatment of moderate to severe pain during sexual intercourse (dyspareunia), a symptom of vulvar and vaginal atrophy (VVA) due to menopause.
- Continued recruitment of patients for the Replenish Trial, a phase 3 clinical trial of TX-001HR, a combination estradiol and progesterone product candidate, for the treatment of moderate to severe vasomotor symptoms due to menopause.
- Ended the quarter with $67.2 million in cash and no debt.
- Accomplished an underwritten public offering of common stock in July 2015 that resulted in net proceeds to the company of about $32.2 million.
- Grew the company’s intellectual property portfolio to a current total of 111 patent filings, of which 61 were filed in international jurisdictions, counting three allowed and 11 issued U.S. patents.
- Supported scientific abstracts and presentations at meetings of the American College of Obstetricians and Gynecologists (ACOG) and the European Society of Menopause and Andropause.
- Continued to develop relationships with key medical and industry organizations.
TherapeuticsMD, Inc. operates as a women’s health care product company. The company manufactures and distributes prescription and over-the-counter product lines, counting prenatal vitamins, iron supplements, vitamin D supplements, and natural menopause relief products under the vitaMedMD brand, in addition to duplicate formulations of its prescription prenatal vitamins products under the BocaGreenMD Prena1 name.
At the end of Wednesday’s trade, Shares of Northern Oil & Gas, Inc. (NYSEMKT:NOG), gained 5.04% to $5.42.
Northern Oil and Gas, Inc. (NYSE MKT: NOG), declared 2015 second quarter results.
2015 second Quarter Highlights
- Production averaged 16,610 barrels of oil equivalent (“Boe”) per day, for a total of 1,511,554 Boe, an 8% enhance over the second quarter of 2014
- Oil and gas sales, counting settled derivatives (hedges), totaled $94.0 million
- Northern added 68 gross (6.9 net) wells to production during the second quarter
- About 2.9 million barrels of oil are hedged for the next four calendar quarters at an average price of about $90.00 per barrel
- Improved liquidity position with $185 million of net proceeds from the May 2015 senior notes offering
- $7.3 million weighted average AFE cost for wells consented to during the second quarter, down 21% from 2014
Northern’s adjusted net income for the second quarter of 2015 was $11.5 million, or $0.19 per diluted share. Adjusted net income was negatively influenced by low natural gas, NGL and oil prices. GAAP net loss for the second quarter of 2015, which was influenced by a $282.0 million non-cash impairment charge, was $250.1 million, or a loss of $4.12 per diluted share. Adjusted EBITDA for the second quarter of 2015 was $70.4 million, an enhance of 4% contrast to the first quarter of 2015. See “Non-GAAP Financial Measures” below for additional information on these measures.
Northern Oil and Gas, Inc., an independent energy company, engages in the acquisition, exploration, development, and production of oil and natural gas properties in the United States.
Finally, Talen Energy Corporation (NYSE:TLN), ended its last trade with 3.99% gain, and closed at $15.10.
Talen Energy Corporation, stated second quarter 2015 Adjusted EBITDA of $171 million, contrast with $126 million in the second quarter of 2014, and net income of $26 million, contrast with $13 million for the second quarter of 2014.
For the first six months of 2015, Adjusted EBITDA was $408 million, contrast with $361 million in the first six months of 2014, and net income was $122 million, contrast with a net loss of $53 million for the first six months of 2014.
“Strong operational performance from our nuclear and gas generation assets led to improved financial results in the quarter,” said Paul Farr, President and Chief Executive Officer of Talen Energy.
Talen Energy Corporation operates as an independent power producer in the United States. It has a portfolio of carbon-free nuclear power, natural gas generation, and coal-fired generation assets.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
